CRVS
Price
$5.15
Change
+$0.06 (+1.18%)
Updated
Sep 27 closing price
33 days until earnings call
PTGX
Price
$44.56
Change
-$0.37 (-0.82%)
Updated
Sep 27 closing price
39 days until earnings call
Ad is loading...

CRVS vs PTGX

Header iconCRVS vs PTGX Comparison
Open Charts CRVS vs PTGXBanner chart's image
Corvus Pharmaceuticals
Price$5.15
Change+$0.06 (+1.18%)
Volume$151.48K
CapitalizationN/A
Protagonist Therapeutics
Price$44.56
Change-$0.37 (-0.82%)
Volume$661.88K
CapitalizationN/A
View a ticker or compare two or three
CRVS vs PTGX Comparison Chart
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CRVS vs. PTGX commentary
Sep 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and PTGX is a Hold.

COMPARISON
Comparison
Sep 28, 2024
Stock price -- (CRVS: $4.04 vs. PTGX: $41.41)
Brand notoriety: CRVS and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 157% vs. PTGX: 60%
Market capitalization -- CRVS: $322.14M vs. PTGX: $2.62B
CRVS [@Biotechnology] is valued at $322.14M. PTGX’s [@Biotechnology] market capitalization is $2.62B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.37B to $0. The average market capitalization across the [@Biotechnology] industry is $3.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whilePTGX’s FA Score has 1 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • PTGX’s FA Score: 1 green, 4 red.
According to our system of comparison, PTGX is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 2 TA indicator(s) are bullish while PTGX’s TA Score has 4 bullish TA indicator(s).

  • CRVS’s TA Score: 2 bullish, 4 bearish.
  • PTGX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, PTGX is a better buy in the short-term than CRVS.

Price Growth

CRVS (@Biotechnology) experienced а -0.74% price change this week, while PTGX (@Biotechnology) price change was -2.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.80%. For the same industry, the average monthly price growth was +5.34%, and the average quarterly price growth was -8.06%.

Reported Earning Dates

CRVS is expected to report earnings on Oct 31, 2024.

PTGX is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+3.80% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($2.63B) has a higher market cap than CRVS($322M). CRVS YTD gains are higher at: 129.545 vs. PTGX (80.593).
CRVSPTGXCRVS / PTGX
Capitalization322M2.63B12%
EBITDAN/AN/A-
Gain YTD129.54580.593161%
P/E RatioN/A16.38-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CRVS vs PTGX: Fundamental Ratings
CRVS
PTGX
OUTLOOK RATING
1..100
2615
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
3536
P/E GROWTH RATING
1..100
9824
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PTGX's Valuation (65) in the Biotechnology industry is in the same range as CRVS (67) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to CRVS’s over the last 12 months.

PTGX's Profit vs Risk Rating (42) in the Biotechnology industry is somewhat better than the same rating for CRVS (100) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew somewhat faster than CRVS’s over the last 12 months.

PTGX's SMR Rating (95) in the Biotechnology industry is in the same range as CRVS (97) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as PTGX (36) in the Biotechnology industry. This means that CRVS’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's P/E Growth Rating (24) in the Biotechnology industry is significantly better than the same rating for CRVS (98) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew significantly faster than CRVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSPTGX
RSI
ODDS (%)
Bearish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
Stochastic
ODDS (%)
Bearish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
Momentum
ODDS (%)
N/A
Bullish Trend about 1 month ago
0%
MACD
ODDS (%)
N/A
Bullish Trend about 1 month ago
0%
TrendWeek
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
TrendMonth
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
Advances
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
Declines
ODDS (%)
Bearish Trend about 2 months ago
0%
Bearish Trend about 2 months ago
0%
BollingerBands
ODDS (%)
Bearish Trend about 1 month ago
0%
N/A
Aroon
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
View a ticker or compare two or three
Ad is loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME23.14-0.28
-1.20%
GameStop Corp
TSLA210.60-3.51
-1.64%
Tesla
SPY552.08-11.60
-2.06%
SPDR® S&P 500® ETF Trust
AAPL222.77-6.23
-2.72%
Apple
BTC.X57431.023000-1681.457000
-2.84%
Bitcoin cryptocurrency

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with KROS. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then KROS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-9.82%
KROS - CRVS
36%
Loosely correlated
+5.38%
RCUS - CRVS
35%
Loosely correlated
-3.21%
PTGX - CRVS
35%
Loosely correlated
-3.45%
VRDN - CRVS
34%
Loosely correlated
-1.43%
NTLA - CRVS
34%
Loosely correlated
-3.65%
More

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with PCVX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then PCVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
-3.45%
PCVX - PTGX
46%
Loosely correlated
+36.39%
NTLA - PTGX
45%
Loosely correlated
-3.65%
VRDN - PTGX
45%
Loosely correlated
-1.43%
VIR - PTGX
44%
Loosely correlated
-5.81%
FOLD - PTGX
41%
Loosely correlated
+0.17%
More